---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-24-000073"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:15:55.672085+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulmonx reports record Q2 revenue $20.8M (+21% YoY); net loss narrows to $15.3M

## Summary
- Worldwide revenue $20.8M, up 21% YoY; U.S. revenue $13.9M (+26%); International $6.9M (+12%).
- Net loss $15.3M ($0.39/share) vs $16.2M ($0.43) in Q2 2023; adjusted EBITDA loss $7.6M vs $10.3M.
- Gross margin held at 74%; operating expenses $30.9M, including $1.7M one-time software impairment.
- Added 17 new U.S. Zephyr Valve treatment centers; first U.S. patients treated in AeriSeal CONVERT II trial.
- Full-year 2024 guidance reaffirmed: revenue $81-84M, gross margin 74-75%, opex $127-129M.

## SEC filing metadata
- accession: 0001127537-24-000073
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000073/0001127537-24-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000073/lung-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-24-000073
- JSON: https://secwatch.observer/filing/0001127537-24-000073.json
- Plain text: https://secwatch.observer/filing/0001127537-24-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.